The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

Biotech stocks witnessed a slowdown in momentum last week, which was a relatively slow one in terms of news flow. Amgen, Inc. (NASDAQ: AMGN)'s unique drug to treat osteoporosis in postmenopausal women at high risk of a fracture cleared the FDA hurdle after an earlier unsuccessful attempt.

The highlights of the week were presentations at the European Association for the Study of the Liver, or EASL, International Liver Congress held in Vienna, Austria.

Here are some key catalysts on tap for the unfolding week.